Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Signs Letter of Intent with Large Multinational Pharmaceutical Company (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Healthcare Biotechnology
Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

biOasis Technologies Ord Shs > The Real Pandemic
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(40)
•••
Comment by zwerp2000on Apr 28, 2021 7:38am
130 Views
Post# 33080813

RE:RE:The Real Pandemic

RE:RE:The Real PandemicJD has been breaking down for quite awhile now. You can see from his posts he is not well. All of these years of spewing the same garbage only to see the stock do nothing and see nothing he's said come true has driven him mad. Nothing this company has said they are going to do has happened. They've been working on their technology for years and years and nothing is even in phase 1 yet. You could argue this company is a scam. The stock price has done nothing in years except go down besides record highs being set in the stock market. This investment has been a total dud yet JD will insinuate he's been right and he knows things and has uncovered things from his amazing DD that we haven't. Of course go back and read his posts from years ago and you'll see he was saying the same things then too. A truly sad individual 
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities